Drug intelligence / Profile preview

ZIKV E + 102CpG

Development stage: Preclinical
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ZIKV E + 102CpG is an experimental Zika virus vaccine candidate that combines recombinant Zika virus envelope protein (E protein, ZIKV E) with the immunostimulatory CpG oligonucleotide "102CpG"[5][6]. The ZIKV E protein, the main surface glycoprotein of Zika virus, is responsible for host-cell entry and is a major target for neutralizing antibody responses[5][11]. CpG oligonucleotides act as adjuvants that activate the innate immune system via Toll-like receptor 9 (TLR9), enhancing the adaptive immune response to the E protein[6]. This combination aims to generate strong and specific Zika-neutralizing antibodies and robust cellular immunity. As of October 2025, ZIKV E + 102CpG is an investigational subunit vaccine in preclinical research, primarily indicated for prophylactic immunization against Zika virus infection.

Brand names: ZIKV E + 102CpG
Other names: ZIKV E + 102CpG

Targets

TLR9 (Toll-like receptor 9)Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on ZIKV E + 102CpG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZIKV E + 102CpG.

Explore the full profile